The work aims to propose preliminary reflections upon a managerial view concerning the open issue of Orphan Drugs. After an overview of the scenario of Orphan Drugs at an international level and a short literature review, the work highlights a dominant economic rationality, which essentially follows a ‘linear’ logic, in the approach to frame the problem of Orphan Drugs both from a policy making and a scientific perspective. By widening the view in the framing of the problem, a more radical change appears to be required in order to overcome the dilemma of reconciling the economic and the social perspectives and be able to address the issue of Orphan Drugs accordingly. A deep rethinking of business models within the context of the worldwi...
ABSTRACTWe argue that orphan drug policies have been useful in incentivizing socially desirable R&D ...
ABSTRACTIt was not until a few decades ago that orphan drugs, still enjoyed†the status of pharmace...
Orphan diseases pose both a challenge to the global medical community and an opportunity for it to f...
The work aims to propose preliminary reflections upon a managerial view concerning the open issue of...
While orphan drug regulations have proven to be an effective tool in stimulating the development of ...
While orphan drug regulations have proven to be an effective tool in stimulating the development of ...
This work is about how healthcare issues can be reframed from a sustainable and inclusive developmen...
BackgroundConcerns about the high cost of orphan drugs has led to questions being asked about the ge...
Concerns about the high cost of orphan drugs has led to questions being asked about the generosity o...
Abstract Pricing and reimbursement of orphan drugs are an issue of high priority for policy makers, ...
This paper explores the decision faced by a firm to invest in an orphan drug development project. Tw...
International audienceAbout 5000 identified diseases are classed as orphan because of the lack of di...
This work is about how healthcare issues can be reframed from a sustainable and inclusive developmen...
ABSTRACTWe argue that orphan drug policies have been useful in incentivizing socially desirable R&D ...
ABSTRACTIt was not until a few decades ago that orphan drugs, still enjoyed†the status of pharmace...
Orphan diseases pose both a challenge to the global medical community and an opportunity for it to f...
The work aims to propose preliminary reflections upon a managerial view concerning the open issue of...
While orphan drug regulations have proven to be an effective tool in stimulating the development of ...
While orphan drug regulations have proven to be an effective tool in stimulating the development of ...
This work is about how healthcare issues can be reframed from a sustainable and inclusive developmen...
BackgroundConcerns about the high cost of orphan drugs has led to questions being asked about the ge...
Concerns about the high cost of orphan drugs has led to questions being asked about the generosity o...
Abstract Pricing and reimbursement of orphan drugs are an issue of high priority for policy makers, ...
This paper explores the decision faced by a firm to invest in an orphan drug development project. Tw...
International audienceAbout 5000 identified diseases are classed as orphan because of the lack of di...
This work is about how healthcare issues can be reframed from a sustainable and inclusive developmen...
ABSTRACTWe argue that orphan drug policies have been useful in incentivizing socially desirable R&D ...
ABSTRACTIt was not until a few decades ago that orphan drugs, still enjoyed†the status of pharmace...
Orphan diseases pose both a challenge to the global medical community and an opportunity for it to f...